Skip to main content
Smart Investors Daily
DT

NASDAQ · DTIL

Precision BioSciences, Inc.

Healthcare · Biotechnology

$7.28

Down-$0.29 (-3.77%)

Updated Nov 17, 2026, 3:15 AM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
64.95M
P/E ratio
-0.69
Dividend yield
0.00%
52-week range
$3.53 – $11.29
Volume
204.41K
Avg. volume
180.03K

Price performance · DTIL

DTIL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

DTIL closed at $7.28 after 21 trading sessions, up 17.61% for the selected period.

Last close
$7.28
Period change
+17.61%
Period low
$6.19
Period high
$10.60
Daily close
View OHLC price history
DTIL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$7.52$7.635$7.25$7.28204.41K
Nov 13, 2026$8.15$8.16$7.52$7.565394.64K
Nov 12, 2026$8.97$9.00$7.9716$8.04414.48K
Nov 11, 2026$9.46$9.585$8.93$9.15251.72K
Nov 10, 2026$9.60$10.02$9.22$9.50352.81K
Nov 9, 2026$10.715$10.81$9.615$9.68590.23K
Nov 6, 2026$9.80$10.78$9.07$10.601.23M
Nov 5, 2026$8.49$11.29$8.40$9.872.91M
Nov 4, 2026$7.205$8.13$7.14$8.12402.07K
Nov 3, 2026$6.95$7.20$6.64$6.97144.84K
Nov 2, 2026$7.06$7.42$6.82$6.95167.79K
Oct 30, 2026$7.31$7.42$6.97$7.06108.93K
Oct 29, 2026$7.50$7.82$7.37$7.44165.74K
Oct 28, 2026$6.76$7.50$6.66$7.47189.67K
Oct 27, 2026$6.39$6.81$6.29$6.79164.25K
Oct 26, 2026$6.68$6.8763$6.37$6.41266.68K
Oct 23, 2026$6.73$6.73$6.29$6.64275.53K
Oct 22, 2026$6.70$6.925$6.58$6.78132.43K
Oct 21, 2026$6.62$6.86$6.545$6.71231.04K
Oct 20, 2026$6.09$6.67$6.09$6.56213.66K
Oct 19, 2026$5.80$6.21$5.77$6.19176.47K

Latest DTIL news

The latest Smart Investors Daily articles mentioning DTIL.

DTIL research

Overview

Company profile and research snapshot.

Company profile

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.50
Implied upside
—
Analysts
10
DTIL recent ratings
DateFirmRatingTarget
Aug 3, 2026HC Wainwright & Co.Buy—
Jul 9, 2026HC Wainwright & Co.Buy—
Jun 9, 2026OppenheimerOutperform—
May 27, 2026HC Wainwright & Co.Buy—
May 21, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering

Precision BioSciences (DTIL) announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Prec

Yahoo · Nov 5, 2026

Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

DURHAM, N.C., November 05, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stoc

Yahoo · Nov 5, 2026

Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study

DURHAM, N.C., November 05, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the first patient treated with PBGENE-DMD in the Phase 1/2 FUNCTION-DMD clinical trial for Duchenne muscular dystrophy (DMD). No serious adverse ev

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.